Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2012; 18(12): 1357-1364
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357
Published online Mar 28, 2012. doi: 10.3748/wjg.v18.i12.1357
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
Romain Altwegg, Marc Ychou, Vanessa Guillaumon, Simon Thezenas, Pierre Senesse, Nicolas Flori, Thibault Mazard, Ludovic Caillo, Stéphanie Faure, Emmanuelle Samalin, Eric Assenat, the Oncology and Digestive Endoscopy Department of the CRLC Val d'Aurelle, 34000 Montpellier, France
Author contributions: Altwegg R and Assenat E contributed equally to this work; Ychou M and Assenat E contributed to conception and design of this study; Altwegg R wrote this paper; Mazard T, Flori N and Caillo L performed acquisition of data; Thezenas S and Faure S performed analysis and interpretation of data; Guillaumon V, Senesse P, Samalin E and Assenat E critically revised this paper.
Correspondence to: Romain Altwegg, MD, the Oncology and Digestive Endoscopy Department of CRLC Val d’Aurelle, 34000 Montpellier, France. romain.altwegg@free.fr
Telephone: +33-608-714230 Fax: +33-467-613729
Received: December 16, 2010
Revised: February 7, 2012
Accepted: February 27, 2012
Published online: March 28, 2012
Revised: February 7, 2012
Accepted: February 27, 2012
Published online: March 28, 2012
Core Tip